Search

Displaying results 501 - 510 of 4591 in total
  1. Drug

    Imdevimab

    go.drugbank.com/drugs/DB15940
    ApprovedInvestigational

    [L23524] In November 2021, the same indication was approved by the EMA. … [A221495] On November 21, 2020, the FDA authorized emergency approval of REGN-COV2 to treat mild to moderate COVID-19 in patients aged 12 years and older.

  2. Drug

    Hydroxyethyl cellulose

    go.drugbank.com/drugs/DB11602
    Approved

    It is often used as an ingredient in ophthalmic pharmaceutical preparations such as artificial tear solutions and adjunct agent in topical drug formulations to facilitate the delivery of drugs with hydrophobic

  3. Drug

    Insulin degludec

    go.drugbank.com/drugs/DB09564
    ApprovedInvestigational

    A18563,A18564,A174934] Due to its duration of action, Tresiba is considered "basal insulin" as it provides low concentrations of background insulin that can keep blood sugar stable between meals or overnight … Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.

    Mixtures: Ryzodeg® FlexTouch® 100 U/ml Solution for Injection, RYZODEG PENFİLL 100 U/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KARTUŞ, 5 ADETProducts: TRESIBA® 100 U/ML, Tresiba® FlexTouch® 100 U/ml Solution for Injection
  4. Drug

    Plant-based virus-like particles, recombinant, adjuvanted COVID-19 vaccine

    go.drugbank.com/drugs/DB16757
    Approved

    The Covifenz COVID-19 vaccine (plant-based virus-like particles (VLP), recombinant, adjuvanted) is a plant-based vaccine developed in partnership by Medicago and GlaxoSmithKline which is approved in Canada

  5. Drug

    Methylphenidate

    go.drugbank.com/drugs/DB00422
    ApprovedInvestigational

    When provided as Concerta®, methylphenidate is released through the patented Osmotic Controlled-Release Oral Delivery (OROS) system where 22% of the dose is provided as an immediate release and 78% is … [F4474] When provided as Biphentin®, methylphenidate is released through a multi-layer release delivery system (MLRTM) where 40% of the dose is provided as an immediate release and 60% is provided through

  6. Drug

    Atogepant

    go.drugbank.com/drugs/DB16098
    ApprovedInvestigational

    It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021. … [L44642] It also received approval for preventive treatment of adult migraine by the EMA in August 2023.

  7. Drug

    Chlorhexidine

    go.drugbank.com/drugs/DB00878
    ApprovedInvestigationalVet approvedWithdrawn

    [L11518,L11512,A190453] Chlorhexidine was developed in the UK by Imperial Chemical Industries in the early 1950s[A190474] and was introduced to the US in the 1970s. … [A190417] The molecule itself is a cationic bis-guanide consisting of two 4-chlorophenyl rings and two biguanide groups joined by a central hexamethylene chain.

  8. Drug

    Propylene glycol

    go.drugbank.com/drugs/DB01839
    ApprovedInvestigational

    A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.

    Mixtures: SYSTANE ULTRA (UD) (LUBRICANT EYE DROPS), SK Lubricant Eye DropsCategories: Drug Delivery Systems
  9. Drug

    Mitapivat

    go.drugbank.com/drugs/DB16236
    ApprovedInvestigational

    [A245478] On February 17, 2022, the FDA approved mitapivat as the first disease-modifying treatment for hemolytic anemia in adults with pyruvate kinase (PK) deficiency, a rare, inherited disorder leading

  10. Drug

    AT1022

    go.drugbank.com/drugs/DB04995
    Experimental

    AT1022 is a hydromorphone skin patch designed to provide rapid and sustained delivery of a potent opiate for the management of severe pain. … AT1022 incorporates PassPort(TM) system, developed to deliver protein and peptide drugs, small-molecule drugs, genes and vaccines across the skin for local and systemic effect.